Live Breaking News & Updates on Clinical

Stay informed with the latest breaking news from Clinical on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Clinical and stay connected to the pulse of your community

Dimerix raises AU$20M on positive phase III kidney disease data

Dimerix Ltd. announced a AU$20 million ($US13.22 million) capital raise following the news that its lead candidate, DMX-200, was successful in a prespecified interim analysis of the efficacy endpoint in its pivotal phase III trial in focal segmental glomerulosclerosis, a rare kidney disease.

Dimerix-ltd , Dimerix-ltd- , Dmx-200 , Focal-segmental-glomerulosclerosis , Kidney-disease , Proteinuria , Propagermanium , Bioworld , Bioworld-asia , Financings , Asia-pacific

Ironwood's apraglutide wins in short bowel but CIC questioned

Positive phase III data from Ironwood Pharmaceuticals Inc. with once-weekly glucagon-like peptide-2 analogue apraglutide failed to impress Wall Street, and shares of the Boston-based firm (NASDAQ:IRWD) closed Feb. 29 at $9.43, down $5.69, or 37.6%. The experiment called Stars tested apraglutide to reduce parenteral support in adults with short bowel syndrome with intestinal failure. Rare and severe, the condition affects about 18,000 adults in the U.S., Europe and Japan. Based on the latest data, Ironwood plans to submit an NDA to the U.S. FDA and other regulatory filings.

Boston , Massachusetts , United-states , Japan , Nasdaq , Ironwood-pharmaceuticals-inc , Ironwood-pharmaceuticals , Wall-street , Ironwood-pharmaceuticals-inc- , Apraglutide , Short-bowel-syndrome

Me-two drug? Viking mid-stage trial wins with GLP-1/GIP bid

The enticing prospect – and proven worth – of dually agonizing the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors gained more evidence in a big way from Viking Therapeutics Inc. with VK-2735 in a phase II weight loss study. Shares of San Diego-based Viking Therapeutics Inc. (NASDAQ:VKTX) closed Feb. 27 at $85.05, up $46.57, or 121%, as investors learned that the drug achieved the primary and all secondary endpoints in the phase II study called Venture, with significant body-weight drops at all doses compared to placebo.

Nasdaq , San-viking-therapeutics-inc , Therapeutics-inc , Viking-therapeutics , San-diego-based-viking-therapeutics , Viking-therapeutics-inc- , Vk-2735 , Glp-1 , Gip , Bioworld , Clinical

BEYOND CHEMO AND CLINICAL TRIALS

societyBreast cancer, a pervasive global health concern, is increasingly making its presence felt among young women in the subcontinent. While traditionally perceived as a disease affecting older age groups, recent trends point to a disturbing rise...

New-delhi , Delhi , India , Karachi , Sindh , Pakistan , Dhaka , Bangladesh , Sri-lanka , Nepal , Sara-danial , World-health-organization

What is Informed Consent?

Informed consent represents one of the most important ethical aspects of clinical treatments and scientific research involving humans.

Greece , United-states , United-kingdom , America , Satyanarayana-rao , Pressmaster-shutterstock , Intj-environ-res-public-health , Oxford-university , Johns-hopkins-university , Oxford-university-press , Silent-world , Johns-hopkins-university-press

Is Alzheimer's the same as dementia? A brain expert explains

A breakthrough new drug to treat brain disease is always welcome news. Last summer, the performance of the drugs donanemab and lecanemab in clinical trials...

United-kingdom , Germany , German , Alois-alzheimer , David-cox , Regulatory-agency , Alzheimer-research-united-kingdom , Research-united-kingdom , Is , Alzheimers , The , Same

Rapt slapped with phase II hold on CCR4 prospect

On the verge of top-line data from its phase IIb trial with oral small-molecule CC chemokine receptor 4 (CCR4) antagonist zelnecirnon in atopic dermatitis (AD), due around the middle of this year, Rapt Therapeutics Inc. said the U.S. FDA has imposed a clinical hold on that study with the otherwise promising drug, also known as RPT-193, in AD as well as the phase IIa trial with the same compound in asthma.

Rapt-therapeutics-inc , Rapt-therapeutics , Rapt-therapeutics-inc- , Zelnecirnon , Rpt-193 , Atopic-dermatitis , Asthma , Clinical-hold , Bioworld , Clinical , Respiratory

Clinical psychologist Marie de Hennezel visits Whangārei to talk death and ageing

World-renowned French clinical psychologist and psychotherapist Marie de Hennezel is in Whangārei to share her expertise on death and ageing well. She sat...

New-zealand , Hennezel , Lorraine , France , Northland , New-zealand-general- , New-zealanders , French , Katy-mandeno , French-ministry-of-health , Northland-rugby-club-rooms-on-riverside-dr , World-renowned-french

Live by the SORD: Applied Therapeutics looks to rare disease NDA

Based on positive phase III study data, Applied Therapeutics Inc. plans to take its CNS-penetrant aldose reductase inhibitor to the U.S. FDA to talk about an NDA for treating the rare disease sorbitol dehydrogenase (SORD) deficiency. SORD, a hereditary axonal neuropathy created by sorbitol dehydrogenase gene mutations, affects about 3,300 people in the U.S. and about 4,000 in Europe, according to Applied Therapeutics.

Therapeutics-inc , Applied-therapeutics , Applied-therapeutics-inc- , Govorestat , At-007 , Sorbitol-dehydrogenase-deficiency , Sord , Rare-disease , Bioworld , Clinical , Neurology-psychiatric